SKP2 and non-small cell lung carcinoma: Together, these results suggest that the Skp2-ubiquitinated MLKL degradation plays a critical role in cisplatin resistance and that combining cisplatin with Skp2 inhibitors could be a promising strategy to overcome chemoresistance in NSCLC cells.